This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith-Jones, P. M. Articles by Bander, N. H. Search for Related Content PubMed PubMed Citation Articles by Smith-Jones, P. M. Articles by Bander, N. H.

In Vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-specific Membrane Antigen¹

Division of Nuclear Medicine, Department of Radiology [P. M. S-J., S. V., S. J. G., C. J. H., D. B.], and Laboratory of Urological Oncology, Department of Urology [V. N., N. H. B.], New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York 10021

Prostate-specific membrane antigen (PSMA) is a well-characterized cell surface antigen expressed by virtually all prostate cancers (PCas). PSMA has been successfully targeted in vivo with ¹¹¹In-labeled 7E11 monoclonal antibody (mAb; ProstaScint; Cytogen, Princeton, NJ), which binds to an intracellular epitope of PSMA. This work reports the in vitro characterization of three recently developed mAbs that bind the extracellular domain of PSMA (PSMA_ext). Murine mAbs J415, J533, J591, and 7E11 were radiolabeled with ¹³¹I and evaluated in competitive and saturation binding studies with substrates derived from LNCaP cells. J415 and J591 were conjugated to 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid labeled with ¹¹¹In. The uptake and cellular processing of these antibodies were evaluated in viable LNCaP cells. All four mAbs could be labeled with ¹³¹I up to a specific activity of 350 MBq/mg with no or little apparent loss of immunoreactivity. Competition assays revealed that J415 and J591 compete for binding to PSMA_ext antigen. J533 bound to a region close to the J591 binding epitope, but J533 did not interfere with J415 binding to PSMA. mAb 7E11 did not inhibit the binding of J415, J533, or J591 (or vice versa), consistent with earlier work that these latter mAbs bind PSMA_ext whereas 7E11 binds the intracellular domain of PSMA. Saturation binding studies demonstrated that J415 and J591 bound with a similar affinity (K_ds 1.76 and 1.83 nM), whereas J533 had a lower affinity (K_d, 18 nM). In parallel studies, all four mAbs bound to a similar number of PSMA sites expressed by permeabilized cells (1,000,000–1,300,000 sites/cell). In parallel studies performed with viable LNCaP cells, J415, J533, and J591 bound to a similar number of PSMA sites (i.e., 600,000–800,000 sites/cell), whereas 7E11 bound only to a subpopulation of the available PSMA sites (95,000 sites/cell). This apparent binding of 7E11 to viable cells can be accounted for by a 5–7% subpopulation of permeabilized cells produced when the cells were trypsinized and suspended. Up to five DOTA chelates could be bound to either J415 or J591 without compromising immunoreactivity. A comparison of the cellular uptake and metabolic processing of the ¹³¹I- and ¹¹¹In-labeled antibodies showed a rapid elimination of ¹³¹I from the cell and a high retention of ¹¹¹In. All four mAbs recognized and bound to similar numbers of PSMAs expressed by ruptured LNCaP cells (i.e., the exposed intracellular and extracellular domains of PSMA). By comparison to J415 and J591, J533 had a lower binding affinity. Both J415 and J591 recognized and bound to the same high number of PSMAs expressed by intact LNCaP. By contrast, 7E11 bound to fewer sites expressed by intact LNCaP cells (i.e., the exposed extracellular domain of PSMA). Both J415 and J591 are promising mAbs for the targeting of viable PSMA-expressing tissue with diagnostic and therapeutic metallic radionuclides.

This article has been cited by other articles:

				S. M. Hillier, K. P. Maresca, F. J. Femia, J. C. Marquis, C. A. Foss, N. Nguyen, C. N. Zimmerman, J. A. Barrett, W. C. Eckelman, M. G. Pomper, et al. Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer Cancer Res., September 1, 2009; 69(17): 6932 - 6940. [Abstract] [Full Text] [PDF]

				U. Elsasser-Beile, G. Reischl, S. Wiehr, P. Buhler, P. Wolf, K. Alt, J. Shively, M. S. Judenhofer, H.-J. Machulla, and B. J. Pichler PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen J. Nucl. Med., April 1, 2009; 50(4): 606 - 611. [Abstract] [Full Text] [PDF]

				J. V. Frangioni New Technologies for Human Cancer Imaging J. Clin. Oncol., August 20, 2008; 26(24): 4012 - 4021. [Abstract] [Full Text] [PDF]

				N. Pandit-Taskar, J. A. O'Donoghue, M. J. Morris, E. A. Wills, L. H. Schwartz, M. Gonen, H. I. Scher, S. M. Larson, and C. R. Divgi Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy J. Nucl. Med., July 1, 2008; 49(7): 1066 - 1074. [Abstract] [Full Text] [PDF]

				R. Balhorn, S. Hok, P. A. Burke, F. C. Lightstone, M. Cosman, A. Zemla, G. Mirick, J. Perkins, A. Natarajan, M. Corzett, et al. Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia Clin. Cancer Res., September 15, 2007; 13(18): 5621s - 5628s. [Abstract] [Full Text] [PDF]

				P. Misra, V. Humblet, N. Pannier, W. Maison, and J. V. Frangioni Production of Multimeric Prostate-Specific Membrane Antigen Small-Molecule Radiotracers Using a Solid-Phase 99mTc Preloading Strategy J. Nucl. Med., August 1, 2007; 48(8): 1379 - 1389. [Abstract] [Full Text] [PDF]

				K. Rege, S. J. Patel, Z. Megeed, and M. L. Yarmush Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells Cancer Res., July 1, 2007; 67(13): 6368 - 6375. [Abstract] [Full Text] [PDF]

				D. Ma, C. E. Hopf, A. D. Malewicz, G. P. Donovan, P. D. Senter, W. F. Goeckeler, P. J. Maddon, and W. C. Olson Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen Clin. Cancer Res., April 15, 2006; 12(8): 2591 - 2596. [Abstract] [Full Text] [PDF]

				I. Burvenich, S. Schoonooghe, B. Cornelissen, P. Blanckaert, E. Coene, C. Cuvelier, N. Mertens, and G. Slegers In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131-Labeled Monoclonal Antibody 14C5 in a Non-Small Cell Lung Cancer and Colon Carcinoma Model Clin. Cancer Res., October 15, 2005; 11(20): 7288 - 7296. [Abstract] [Full Text] [PDF]

				M. J. Morris, C. R. Divgi, N. Pandit-Taskar, M. Batraki, N. Warren, A. Nacca, P. Smith-Jones, L. Schwartz, W. K. Kelly, S. Slovin, et al. Pilot Trial of Unlabeled and Indium-111-Labeled Anti-Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7454 - 7461. [Abstract] [Full Text] [PDF]

				S. Vallabhajosula, S. J. Goldsmith, L. Kostakoglu, M. I. Milowsky, D. M. Nanus, and N. H. Bander Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity Clin. Cancer Res., October 1, 2005; 11(19): 7195s - 7200s. [Abstract] [Full Text] [PDF]

				N. H. Bander, M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula, and S. J. Goldsmith Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer J. Clin. Oncol., July 20, 2005; 23(21): 4591 - 4601. [Abstract] [Full Text] [PDF]

				S. Vallabhajosula, S. J. Goldsmith, K. A. Hamacher, L. Kostakoglu, S. Konishi, M. I. Milowski, D. M. Nanus, and N. H. Bander Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen J. Nucl. Med., May 1, 2005; 46(5): 850 - 858. [Abstract] [Full Text] [PDF]

				S. Vallabhajosula, I. Kuji, K. A. Hamacher, S. Konishi, L. Kostakoglu, P. A. Kothari, M. I. Milowski, D. M. Nanus, N. H. Bander, and S. J. Goldsmith Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu? J. Nucl. Med., April 1, 2005; 46(4): 634 - 641. [Abstract] [Full Text] [PDF]

				M. D. Henry, S. Wen, M. D. Silva, S. Chandra, M. Milton, and P. J. Worland A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer Cancer Res., November 1, 2004; 64(21): 7995 - 8001. [Abstract] [Full Text] [PDF]

				M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula, S. J. Goldsmith, and N. H. Bander Phase I Trial of Yttrium-90--Labeled Anti--Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer J. Clin. Oncol., July 1, 2004; 22(13): 2522 - 2531. [Abstract] [Full Text] [PDF]

				P. M. Smith-Jones, S. Vallabhajosula, V. Navarro, D. Bastidas, S. J. Goldsmith, and N. H. Bander Radiolabeled Monoclonal Antibodies Specific to the Extracellular Domain of Prostate-Specific Membrane Antigen: Preclinical Studies in Nude Mice Bearing LNCaP Human Prostate Tumor J. Nucl. Med., April 1, 2003; 44(4): 610 - 617. [Abstract] [Full Text] [PDF]

				S. E. Lupold, B. J. Hicke, Y. Lin, and D. S. Coffey Identification and Characterization of Nuclease-stabilized RNA Molecules That Bind Human Prostate Cancer Cells via the Prostate-specific Membrane Antigen Cancer Res., July 15, 2002; 62(14): 4029 - 4033. [Abstract] [Full Text] [PDF]

				M. R. McDevitt, D. Ma, L. T. Lai, J. Simon, P. Borchardt, R. K. Frank, K. Wu, V. Pellegrini, M. J. Curcio, M. Miederer, et al. Tumor Therapy with Targeted Atomic Nanogenerators Science, November 16, 2001; 294(5546): 1537 - 1540. [Abstract] [Full Text] [PDF]

				D. C. Saffran, A. B. Raitano, R. S. Hubert, O. N. Witte, R. E. Reiter, and A. Jakobovits Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts PNAS, February 8, 2001; (2001) 51624698. [Abstract] [Full Text]

				D. C. Saffran, A. B. Raitano, R. S. Hubert, O. N. Witte, R. E. Reiter, and A. Jakobovits Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts PNAS, February 27, 2001; 98(5): 2658 - 2663. [Abstract] [Full Text] [PDF]